

Evaluation of PET-CT Metrics and Pharmacokinetics in Adults Receiving Tisnelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: Ancillary Analyses of LYSA Phase 2 TIRHOL Study BGB-A317-210

PS2028

Hervé Ghesquières,¹ Krimo Bouabdallah,² Salim Kanoun,³ Marc André,⁴ Philippe Quittet,⁵ Cécile Borel,⁶ Aspasia Stamatoullas Bastard,⁷ Michael Gilbertson,⁸ Fabien Le Bras,⁹ Catherine Thieblemont,¹⁰ Baptiste Delapierre,¹¹ Mohamed Touati,¹² Pierre Feugier,¹³ Loïc Renaud,¹⁴ Nadine Morineau,¹⁵ Thomas Gastinne,¹⁶ Isabelle Chaillol,¹⁷ Rod Ramchandren,¹⁸ Harsh Shah,¹⁹ Dipenkumar Modi,²⁰ Heather Allewelt,²¹ Pierre Fustier,²² Xiangyu Liu,²¹ Jun Zhang,²¹ Richard Delarue,²² Franck Morschhauser,²³ Cédric Rossi²⁴

¹Lyon Sud Hospital, Pierre Bénite, France; ²Hôpital Haut-Lévêque, CHU Bordeaux, Pessac, France; ³Institut Universitaire du Cancer de Toulouse, Toulouse, France; ⁴CHU UCL Namur, Yvoir, Belgium; ⁵CHU Montpellier, Montpellier, France; ⁶UCT Oncopole, Toulouse, France; ⁷Centre Henri Becquerel, Rouen, France; ⁸Monash Health, Melbourne, VIC, Australia; ⁹CHU Mondor, Creteil, France; ¹⁰AP-HP, Hôpital Saint-Louis, Hemato-oncology, Paris University Paris Cité, Paris, France; ¹¹Caen University Hospital, Caen, France; ¹²CHU Limoges, Limoges, France; ¹³CHU Nancy, Nancy, France; ¹⁴Gustave Roussy, Department of Hematology, Villejuif, France; ¹⁵CHD de Vendée, La Roche Sur Yon, France; ¹⁶CHU de Nantes, Nantes, France; ¹⁷Lymphoma Academic Research Organisation, Lyon, France; ¹⁸UPMC Hillman Cancer Center, Pittsburgh, PA, USA; ¹⁹University of Utah, Salt Lake City, UT, USA; ²⁰Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA; ²¹BeOne Medicines, Ltd, San Carlos, CA, USA; ²²BeOne Medicines, Ltd, Basel, Switzerland; ²³CHU de Lille, Lille, France; ²⁴CHU Dijon, Dijon, France

CONCLUSIONS

- Tisnelizumab is an effective therapeutic option for patients with R/R cHL
- Analyses of centrally reviewed PET-CT imaging demonstrated a trend for underestimation of local response assessments, and therefore in ORR, likely due to the presence of non-lymphomatous inflammatory lesions
- Tisnelizumab PK and efficacy outcomes did not differ based on baseline PET-CT metrics
- OS was lower in patients without metabolic response at week 12 compared with patients who had CMR or PMR
- Variations in PET-CT parameters during anti–PD-1 therapy should be interpreted with caution to avoid premature treatment discontinuation

INTRODUCTION

- The phase 2 TIRHOL study (NCT04318080) was designed to evaluate the efficacy of the PD-1 inhibitor tisnelizumab in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in Western countries!
 - Overall, 45 patients with R/R cHL were treated with tisnelizumab every 3 weeks until progressive disease, unacceptable toxicity, or study withdrawal; disease response was assessed by the investigator every 12 weeks per Lugano 2014 positron emission tomography–computed tomography (PET-CT) classification
 - The study met its primary endpoint, with an overall response rate (ORR) of 66.7% (95% CI, 51%-80%) and a complete response rate of 31%
 - Pharmacokinetics (PK) profiles were comparable between BGB-A317-210 and the prior Chinese study BGB-A317-203^{2,3}
- Conventional methods using PET-CT to assess lymphoma response are suboptimal in patients treated with PD-1 inhibitors, and specialized criteria are required to prevent premature treatment discontinuation due to inflammation unrelated to disease progression

METHODS

- In this correlative, ancillary analysis of the TIRHOL study, PET-CT imaging was evaluated post hoc by a central, independent reviewer
- The prognostic role of baseline PET-CT metrics was evaluated with correlation of TMTV4, TLG4, Dmax4, SUVmean, SUVmax, and:
 - First and best response assessments (complete metabolic response [CMR], partial metabolic response [PMR], stable disease [SD], and progressive disease [PD])
 - Outcome: progression-free survival (PFS) and overall survival (OS)
- The longitudinal evolution of TMTV4 during tisnelizumab treatment was evaluated
- Tisnelizumab PK profiles (cycle 1 postdose and cycle 2 predose concentrations) were evaluated against baseline clinical and PET-CT characteristics

RESULTS

Clinical Characteristics


- PET-CT imaging at baseline and during follow-up was available for central review for 37 of 45 patients included in TIRHOL
- Patient clinical characteristics are shown in **Table 1**

Table 1. Patient Clinical Characteristics		
Parameters	Central PET-CT cohort n=37	TIRHOL study cohort n=45
Age, median (range), years	53 (18-87)	64 (18-87)
≥45 years, n (%)	25 (67.6)	31 (68.9)
Male, n (%)	26 (70.3)	30 (66.7)
Time since initial diagnosis, median (range), months	23.5 (6-326)	24.7 (6-326)
ECOG PS 1, n (%)	13 (35.1)	17 (37.8)
IPS ≥3, n (%)	17 (47.2)	22 (50.0)
Refractory status at enrollment, n (%)	12 (32.4)	13 (28.9)
No. of prior lines, median (range)	2 (1-4)	2 (1-4)
Prior therapy, n (%)		
Monoclonal antibody	29 (78.4)	34 (75.6)
Chemotherapy	37 (100)	45 (100)
Radiotherapy	7 (18.9)	10 (22.2)
ASCT	12 (32.4)	14 (31.1)
Other anticancer therapy	0	2 (4.4)
Cohort 1 (prior ASCT and BV)	12 (32.4)	14 (31.1)
Cohort 2 (not candidate for ASCT)	25 (67.6)	31 (68.9)

Abbreviations: ASCT, autologous stem cell transplant; BV, brentuximab vedotin; ECOG PS, Eastern Cooperative Oncology Group performance status; IPS, International Prognostic Score; PET-CT, positron emission tomography–computed tomography.

Tisnelizumab PK Profiles

- No differences in PK results were observed based on key baseline categorical variables (sex, age, B-symptoms, inclusion in cohort 1 or 2, Ann Arbor stage, bulk, refractory vs relapsed disease, International Prognostic Score, TMTV4, albumin level) (**Figure 1**)



Response Assessments: Local Investigators vs Central Review

- Analyses of PET-CT imaging demonstrated a trend for underestimation of responses assessed by local investigator vs responses by central review in the ORR (66.7% vs 70%) and CMR rate (31% vs 41%), likely due to the presence of non-lymphomatous inflammatory lesions (**Table 2**)
- CMR was achieved in 10 of 45 (22%) included patients at first evaluation at week 12 per local investigator; on central review, the CMR rate was 27% (**Table 3**)

Table 2. Best Response (Primary Endpoint)

n (%)	Best response, local investigators					
Best response, central review	CMR n=11	PMR n=13	SD n=1	PD n=11	NE n=1	All n=37
CMR	10 (90.9)	5 (38.5)	0	0	0	15 (40.5)
PMR	1 (9.1)	7 (53.8)	1 (100)	2 (18.2)	0	11 (29.7)
SD	0	0	0	1 (9.1)	0	1 (2.7)
PD	0	1 (7.7)	0	8 (72.7)	0	9 (24.3)
NE	0	0	0	0	1 (100)	1 (2.7)

Abbreviations: CMR, complete metabolic response; NE, not evaluated; PD, progressive disease; PMR, partial metabolic response; SD, stable disease.


Table 3. First Response at 12 Weeks

n (%)	First response, local investigators					
First response, central review	CMR n=9	PMR n=11	SD n=1	PD n=14	NE n=1	All n=37
CMR	7 (77.8)	2 (18.2)	1 (50.0)	0	0	10 (27)
PMR	2 (22.2)	7 (63.6)	1 (50.0)	3 (21.4)	0	13 (35)
SD	0	0	0	1 (7.1)	0	1 (2.7)
PD	0	2 (18.2)	0	10 (71.4)	0	12 (32.4)
NE	0	0	0	0	1 (100)	1 (2.7)

Abbreviations: CMR, complete metabolic response; NE, not evaluated; PD, progressive disease; PMR, partial metabolic response; SD, stable disease.


Baseline PET-CT Metrics and Response

- Median baseline PET-CT metrics were comparable across best metabolic response categories (**Figure 2A-E**)
- Similar results were observed with week 12 metabolic response





PET-CT Metrics and Outcome

- The depth of metabolic response at first evaluation (week 12) influenced PFS and OS and was associated with 1-year PFS rates of 60%, 26%, and 8% (**Figure 3A**) and 1-year OS rates of 100%, 100%, and 77% (**Figure 3B**) in patients with best response of CMR (n=10), PMR (n=13), and NMR (n=13), respectively



Longitudinal Evaluations of PET-CT Metrics

- Longitudinal evaluations of TMTV4 (**Figure 4**) and SUVmean (**Figure 5**) showed a rapid decrease in values at first evaluation in patients with CMR and PMR at week 12
- Patterns of TMTV4 and SUV variations during tisnelizumab treatment differed between patients with best metabolic response of CMR, PMR, SD, and PD



REFERENCES

- Ghesquières H, et al. ICM. 2025. Abstract 130.
- Budha N, et al. CPT Pharmacometrics Syst Pharmacol. 2022;12(1):95-109.
- Ghesquières H, et al. ASH 2023. Abstract 1717.

DISCLOSURES

HG: Consultant: Roche, BMS, Takeda, Honoraria: Gilead, Roche, BMS, AbbVie, Takeda. **KB:** Honoraria: Takeda, BeOne Medicines, Ltd, Kite Pharma/Gilead, AstraZeneca; Consulting or advisory role: BeOne Medicines, Ltd, Takeda, Lilly, AstraZeneca; Research funding: Takeda, Travel, accommodations, expenses: Takeda, Lilly, Pierre Fabre, AstraZeneca. **SK:** Other relationship: Founder of Pixel Imaging (CRO); PD: Honoraria and speakers bureau: Novartis. **ASB:** Travel, accommodations, expenses: Takeda, Johnson & Johnson. **CF:** Consulting or advisory role, travel, accommodations, expenses: Novartis, Roche, BMS, Takeda, AbbVie. **MT:** Honoraria: Janssen, Amgen, Roche, AbbVie, BMS, BeOne Medicines, Ltd; Consulting or advisory role: Janssen, Takeda, Amgen; Travel, accommodations, expenses: Amgen, Janssen, BeOne Medicines, Ltd. **LB:** Consulting or advisory role: Janssen, Takeda, BMS, AbbVie. **TG:** Employment, stock or other ownership: Sanofi; Honoraria: Gilead, Kyte, Takeda, BMS; Consulting or advisory role: Gilead, BMS, Takeda; Expert testimony: Takeda, Gilead; Travel, accommodations, expenses: Roche, Gilead, Takeda. **RR:** Speakers bureau: GSK. **HS:** Honoraria: Curio Science, Epizyme, BMS, Seattle Genetics, ADC Therapeutics. **DM:** Honoraria: Regeneron; Consulting or advisory role: AstraZeneca, Daiichi Sankyo, BMS, ADC Therapeutics, Genmab; Research funding (payable to institution): Kayosynth Therapeutics, Genentech, Genmab, AstraZeneca. **HA:** Employment and may own stock: BeOne Medicines, Ltd; Nektar Therapeutics; Patents and royalties: St. Jude Children's Research Hospital; Writing support: BeOne Medicines, Ltd; Travel support: BeOne Medicines, Ltd, Spouse: Nektar, Inc.; Advisory board: BeOne Medicines, Ltd; Leadership role: Board Secretary: Fix Our Ferals, obo Animal Fix Clinic (non-profit surgical clinic for cats and dogs, unrelated to employment or publications); Spouse: Nektar, Inc. **PF:** Employment: BeOne Medicines, Ltd; Stock or other ownership: BeOne Medicines, Ltd, BMS. **XL, JZ, RD:** Employment and may own stock: BeOne Medicines, Ltd. **FM:** Consultant: Roche, BMS, Gilead, Honoraria or speakers bureau: Takeda, Roche, Chugai; Data safety monitoring board or advisory board: Gilead, BMS, AbbVie. **MA, CB, MG, FLB, BD, PF, NM, IC, CR:** No disclosures.

ACKNOWLEDGMENTS

This study was co-sponsored by BeOne Medicines, Ltd and LYSARC. Editorial support was provided by Nucleus Global, an Inizio company, and supported by BeOne Medicines.